Patent ID: 11951133
Assignee: NURIX THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 21:
22. A method of modulating the immune response, the method comprising administering an effective amount of a Cbl-b inhibitor to an individual to modulate the immune response in the individual, wherein the Cbl-b inhibitor is a compound of Formula (I), , or a tautomer thereof, stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, , is, X is CH or nitrogen;
Z1 is CH or nitrogen;
Z2 is CH or nitrogen;
R1a and R1b are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH;
R2a is —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or —(C1-C6 alkylene)-O—(C1-C6 alkyl);
R2b is hydrogen, halo, or C1-C6 alkyl;
or R2a and R2b are taken together with the carbon atom to which they are attached to form a spiro 3- to 6-membered heterocyclyl or a spiro C3-C6 cycloalkyl,
wherein at least one of the atoms of the spiro heterocyclyl which is adjacent to the connecting piperidinyl ring is carbon;

R3a and R3b are independently hydrogen, halo, or C1-C6 alkyl;
or R3a and R3b are taken together with the carbon atom to which they are attached to form C3-C4 cycloalkyl;
R4 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH;, , is, , and Y is CR5aR5b or sulfur;, or, , is, , and Y is a bond;
W is oxygen or a bond;
R5a and R5b are independently hydrogen, halo, or C1-C6 alkyl;
or R5a and R5b are taken together with the carbon atom to which they are attached to form a C3-C6 cycloalkyl;
R6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
R7 is hydrogen, halo, C3-C6 cycloalkyl, —NH—(3- to 6-membered heterocyclyl), —NH—(C1-C6 alkyl), —NH—(C3-C6 cycloalkyl), —O-(3- to 6-membered heterocyclyl), —O—(C1-C6 alkyl), or —O—(C3-C6 cycloalkyl);
R8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
R9 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; and
R10 is —CF3 or cyclopropyl.